Abstract
Breast cancer in India is rapidly expanding overtaking cervical cancer in terms of incidence as well as mortality. Indian women with breast cancer are younger, premenopausal and a large proportion of patients present at advanced stages. Considering breast cancer to be a complex disease demonstrating heterogeneity at clinical and histopathological levels, breast cancer in the Indian population could be biologically dhistology and receptor status characterization ifferent from those of the west. We attempt to study the clinical and pathological aspects of breast cancer and its correlation with biomolecular subtyping with comparison to the western population in order to find a pattern of differences. All patients diagnosed and treated in the Department of Surgical Oncology, King George Medical University, Lucknow, UP, from the period of August 2014 to August 2016 are included. Clinical and histopathological data was recorded. A total of 355 patients were analyzed. Average age of patients with disease was 45.3 years. The premenopausal group consists of 52% of patients. Mostly patients presented in locally advanced stage. Triple-negative disease was associated with higher grade of disease (p < 0.0001) and higher rates of lymphovascular invasion (p = 0.040), pericapsular invasion (p = 0.005), and extranodal spread of disease (p < 0.001).This subgroup was significantly higher in premenopausal patients (p = .016). Disease-free survival was lower in triple-negative group. As compared to the western population, the breast cancer in India presents in younger, premenopausal, multiparous, and breast feeding women. Molecular subgrouping reveals that about 60% of the patients are hormone negative. Forty-three percent of patients were triple negative. It appears to be that breast cancer in India is a different subset from the western world in having different molecular signatures that translate into distinct clinical and histopathological subgroup.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
DeSantis C, Ma J, Bryan L, Jemal A (2014) Breast Cancer Statistics. CA Cancer J Clin 64(1):52–62. https://doi.org/10.3322/caac.21203
Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969-2016) National Cancer Institute, DCCPS, Surveillance Research Program. www.seer.cancer.gov/popdata. Accessed December 2017
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase no. 11 [internet]. International Agency for Research on Cancer, Lyon
Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7(1/2):4–13
Manjunath S, Prabhu JS, Kaluve R, Correa M, Sridhar TS (2011) Estrogen receptor negative breast cancer in india: do we really have higher burden of this subtype? Indian J Surg Oncol 2(2):122–125
Kakarala M, Rozek L, Cote M, Liyanage S, Brenner DE (2010) Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S. - a SEER analysis. BMC Cancer 10:191
Kurian AW, Fish K, Shema SJ, Clarke CA et al (2010) Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res 12:R99
Munjal K, Ambaye A, Evans MF, Mitchell J, Nandedkar S, Cooper K (2010) Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients. Asian Pac J Cancer Prev 10:773–778
Shet T, Agrawal A, Nadkarni M, Palkar M, Havaldar R, Parmar V, Badwe R, Chinoy RF (2009) Hormone receptors over the last 8 years in cancer referral center in India What was and what is. Indian J Pathol Microbiol 52(2):171–174
Su Y, Zheng Y, Zheng W, Gu K, Chen Z, Li G, Cai Q, Lu W, Shu XO (2011) Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer 11:292
Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A (2011) Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev 12:625–629
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Steven A (2007) Narod triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434 Published online August 1, 2007
Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25–32
Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9:R6. https://doi.org/10.1186/bcr1639
Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielson TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376 Published online March 3, 2008
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Paryani, J., Gupta, S. Is Breast Cancer Problem in India Worse Than That of the West? Reflection of Analysis of Breast Cancer Molecular Subtyping from Tertiary Cancer Care Center in Northern India. Indian J Surg 81, 426–431 (2019). https://doi.org/10.1007/s12262-018-1830-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12262-018-1830-4